|
|
|
|
|
Cephalexin
drug data and news
Cephalexin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cephalexin | ||
| Brand Names/Synonyms | Alcephin; Alexin; Alsporin; Biocef; CEX; Carnosporin; Cefa-Iskia; Cefablan; Cefadal; Cefadin; Cefadina; Cefaleksin; Cefalessina [Dcit]; Cefalexin; Cefalexin Sodium; Cefalexina [Inn-Spanish]; Cefalexine [Inn-French]; Cefalexinum [Inn-Latin]; Cefalin; Cefaloto; Cefaseptin; Cefax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexin; Cephalexin Hydrate; Cephalexin Monohydrate; Cephalexine; Cephalexinum; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporex Forte; Ceporexin; Ceporexin-E; Ceporexine; Check; Cophalexin; Durantel; Durantel Ds; Ed a-Ceph; Erocetin; Factagard; Felexin; Fexin; HSDB | ||
| Indication | For the treatment of respiratory, skin, soft tissue, urintary tract infections caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A ß-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cephalexin is a first-generation cephalosporin antibiotic which is effective against most gram-positive bacteria. Cephalexin is used to treat otitis media and respiratory tract infections caused by susceptible staphylococci, Streptococcus pneumoniae, and group A beta-hemolytic streptococci. | ||
| Mechanism Of Action | Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cephalexin interferes with an autolysin inhibitor. | ||
| Cephalexin News (When available) |
Advancis Pharmaceutical Reports Fourth Quarter and Full Year 2005 ... Feb 9, 2006 Advancis Pharmaceutical Strengthens Sales and Marketing Capability ... Feb 28, 2006 GeoPharma Reports 80% Increase in Third Quarter 2006 Revenues; EPS ... Feb 1, 2006 Strep throat grows stronger Feb 3, 2006 Necrotizing Fasciitis in a Patient with Type 2 Diabetes Mellitus Feb 9, 2006 Advancis Pharmaceutical Reports Fourth Quarter and Full Year 2005 ... 09 Feb 2006 Health Groups Raising Awareness on Misuse of Antibiotics Jan 25, 2006 Hikma part-owned plant given FDA approval Jan 25, 2006 GeoPharma Reports 80% Increase in Third Quarter 2006 Revenues; EPS ... Feb 1, 2006 Strep throat grows stronger Feb 3, 2006 Kids tee off Jan 10, 2006 Underground resistance Jan 19, 2006 Retapamulin demonstrates promising activity against pathogens ... Jan 10, 2006 Stock Watch Jan 24, 2006 Lupin gets USFDA nod for Cephalexin Nov 30, 2005 Lupin gets USFDA nod for Cephalexin Dec 1, 2005 Lupin receives USFDA approval for Cephalexin capsules Dec 1, 2005 Lupin receives USFDA approval for Cephalexin Capsules Dec 1, 2005 Lupin receives US FDA approval for Cephalexin capsules Dec 1, 2005 Aurobindo gets US FDA approval for Cephalexin Nov 20, 2005 Aurobindo gets FDA nod for cephalexin capsules Nov 21, 2005 Aurobindo Pharma gets nod for Cephalexin Nov 21, 2005 USFDA approval for Aurobindo's Cephalexin Nov 21, 2005 Lupin gets nod for antibiotic Cephalexin Dec 1, 2005 Real growth will happen from 2007: Orchid Dec 10, 2005 Weekly wrap: Sensex breaches 9000 mark Dec 2, 2005 Aurobindo gets USFDA approval Nov 20, 2005 Market trades weak Nov 21, 2005 Sensex closes in negative territory Nov 21, 2005 Aurobindo Pharma gets nod from US FDA Nov 21, 2005 Indices bounce back strongly from yesterday's fall Dec 1, 2005 Indices finally stump the uprising on profit booking Nov 21, 2005 Dear Doctor: How does MRSA spread? Nov 22, 2005 Advancis Pharmaceutical to Conduct Additional Adult Amoxicillin ... Sep 15, 2005 Advancis Starting Another Trial, Selling Keflex Rights For $12M Sep 15, 2005 Advancis Pharmaceutical to Conduct Additional Adult Amoxicillin ... Sep 15, 2005 Antibiotics keep blood bacteria-free Sep 27, 2005 Through the golden years: A Grandparent’s Day special Sep 10, 2005 Highlights of rising and falling US stocks Sep 15, 2005 Advancis to conduct new Phase III trial Sep 15, 2005 Natural Pets Sep 21, 2005 Cheap branded drugs soon available in Botika ng Bayan Sep 9, 2005 Lupin wins USFDA nod for Cephalexin suspension Aug 18, 2005 Lupin receives USFDA approval for Cephalexin Oral Suspension Aug 20, 2005 Infections in Patients With Diabetes Aug 19, 2005 Selling sweeps away gains @ 12:37 hrs Aug 19, 2005 Orchid to unveil 2 more antibiotics in US Aug 17, 2005 Advancis Pharmaceutical Reports Second Quarter 2005 Results Aug 5, 2005 Beyond boundaries Jul 11, 2005 | ||
| Dosage Forms | SUSPENSION; TABLET | ||
| Drug_Category | Anti-bacterial Agents; Cephalosporins; ATC:J01DB01 | ||
| Absorption | It is rapidly absorbed after oral administration by the gastrointestinal tract | ||
| Interactions |
-->Interactions for Cephalexin: Metformin ó In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug. Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin. Probenecid ó As with other b -lactams, the renal excretion of cephalexin is inhibited by probenecid. Drug / Laboratory Test Interactions As a result of administration of Keflex, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedictís and Fehlingís solutions and also with Clinitest® tablets. -->--> | ||
| Toxicity | Nausea, vomiting, diarrhea, anorexia, abdominal pain, flatulence, pseudomembranous colitis, liver toxicity | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 8-(2-amino-2-phenyl-acetyl)amino-4-methyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid | ||
| Chemical Formula | C16H17N3O4S | ||
| Molecular Weight | 347.39 g/mol | ||
| Smiles String | CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O | ||
| Melting Point | 326.8 °C | ||
| Water Solubility | 1789 mg/L | ||
| State | Solid: white crystalline solid having a bitter taste | ||
| LogP/Hphobicity | 0.019 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Does not undergo appreciable biotransformation in liver | ||
| Half Life | 1hr | ||
| Protein Binding [%] | 14% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cephalexin.html http://www.rxlist.com/cgi/generic/cephalex.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/kef1213.shtml http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00250 | ||
| CAS Registry Number | 15686-71-2 | ||
| KEGG Compound ID | C06895 | ||
| PubChem ID | SID:9112 | ||
| PharmGKB ID | PA448883 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 828858 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |